A Randomized, Controlled, Open -label Short -term Study to Evaluate Changes in Exposure to 
Harmful and Potentially Harmful Constituents in Adult Smokers Who Completely Switch to 
on!® Nicotine Pouches in a Clinical Setting  
[STUDY_ID_REMOVED]  
30JUN2021  
TITLE PAGE  
Protocol  
A Randomized, Controlled, Open -label Short -term Study to Evaluate 
Changes in Exposure to Harmful and Potentially Harmful Constituents in 
Adult Smokers Who Completely Switch to on!® Nicotine Pouches in a 
Clinical Setting  
Protocol Amendment 2 Status: Final  
Original Protocol Date: 09 March 2021 
Protocol Amendment 1 Date: 2 8 April 2021 
Protocol Amendment 2 Date: 30 June 2021 
Protocol Version: 3.0 
Study Product: on!® Nicotine Pouches 
Protocol Reference Number: ALCS -REG -20-15- OTDN  
Covance Study Number: 000000215511 
 
Sponsor:  
Altria Client Services LLC  
601 E ast Jackson Street  
Richmond, Virginia 23219, USA Study Site s: 
QPS  
1820 W est Mount Vernon St reet 
Springfield, Missouri 65802, USA 
 
 NOCCR  
1928 Alcoa Highway , Suite 107  
Knoxville, Tennessee 37920, USA 
 
 CKRA  
3475 Richmond Road 
3rd Floor  
Lexington, Kentucky 40509, USA 
 
Sponsor Signator ies: 
 
 
 
 
 Principal Investigator s: 
  
  
Infor
mation described herein is confidential and may be disclosed only with the express 
written permission of the sponsor. 

Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 2 of 51 SPONSOR APPROVAL  
I have read the protocol and approve it: 
Date  
_________________ ______________________________ 
  Date
______________ ______________________________ 
 Date 
______________ ______________________________ 
  Date
DocuSign Envelope ID: 0D29416F-BC08-4EB7-8C40-1C0BDA170044
6/30/20216/30/2021
6/30/2021
6/30/2021

Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 3 of 51 INVESTIGATOR AGREEMENT  
 
  I have read the protocol and agree to conduct the study as described herein.    
    
Name, Qualifications   Date  
Principal Investigator 
  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 4 of 51 STUDY IDENTIFICATION 
Sponsor  Altria Client Services LLC  
601 E ast Jackson Street  
Richmond, Virginia 23219 , USA  
Sponsor’s Study Contact 
 
 
 
Sponsor’s Medical Contact   
 
 
 
 
 
  
Study Site QPS  
1820 W est Mount Vernon St reet  
Springfield, Missouri 65802 , USA   
Study Site NOCCR  
1928 Alcoa Highwa y, Suite 107  
Knoxville, Tennessee  37920 , USA  
Study Site CKRA  
3475 Richmond Road 
3rd Floor  
Lexington, Kentucky 40509 , USA  
Principal Investigator   
  
 
 
 
 
Principal Investigator   
  
  
  
 

Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 5 of 51 Principal Investigator   
  
 
  
 
 
Sub-investigators Obtain information from Form FDA 1572 
Clinical Laborator ies  Obtain information from Form FDA 1572 
Bioanalytical Laboratories  Analytischbiologisches Forschungslabor GmbH 
(ABF)  
Semmelweisstraße 5,  
82152 Planegg, Germany 
 Celerion  Inc. 
624 Peach Street  
Lincoln, Nebraska 68502 , USA  
Statistician   
 
 

Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 6 of 51 SYNOPSIS  
Study Title  
A Randomized, Controlled, Open- label Short -term Study to Evaluate Changes in Exposure to 
Harmful and Potentially Harmful Constituents in Adult Smokers Who Completely Switch to 
on!® Nicotine Pouches in a Clinical Setting  
Objectives  
The primary objective of the study is: 
• To compare 24 -hour urinary total 4- (methylnitrosamino) -1-(3-pyridyl)-1-butanol 
(NNAL) in subjects using nicotine pouches (NP) for 7 days versus subjects who 
continue to smoke cigarettes for 7 days. 
The secondary objectives of the study are:  
• To compare biomarkers of exposure (BOEs)1 (except total NNAL ) in subjects using 
NP for 7 days versus subjects who continue to smoke cigarettes for 7 days  
• To compare BOEs in subjects using NP  for 7 days versus subjects who stopped using 
any tobacco products for 7 days 
• To characterize product use behaviors (such as: number of cigarettes smoked per day, 
number of NP use per day, number of NPs per use, average duration of each NP use). 
Study Design  
This is an open- label, randomized, 5 parallel -group clinical study evaluating changes in 
exposure to selected harmful and potentially harmful constituents ( HPHC s) and product use 
behavior in adult smokers who are randomly assigned to 1 of the 5 groups; continue smoking (Group 1), completely switch to 2 mg (Group 2), 4 mg (Group 3), or 8 mg (Group 4) on!
® 
NP, or stop using any tobacco products (Group 5) for 7 days. Potential subjects will be 
screened to assess their eligibility to enter the study within 28 days prior to c heck -in (Day -3). 
Subjects will be admitted into the study site on Day -3 and be confined to the study site until 
discharge on Day 8.  
 
 
1 BOEs : Urine: total 4 -(methylnitrosamino) -1-(3-pyridyl) -1-butanol (NNAL), nicotine equivalents (NE), 
2-aminonaphthalene (2 -AN), 4 -aminobiphenyl (4 -ABP), 2 -hydroxyethylmercapturic acid (HEMA), 
cyanoethylmercapturic acid (CEMA), S -phenylmercapturic acid (SPMA), 3- hydroxy-1-
methylpropylmercapturic acid (HMPMA), 3 -hydroxypropylmercapturic acid (3- HPMA), 
2-hydroxypropylmercapturic acid (2- HPMA), N- acetyl -S-(2-carbamoylethyl) cysteine (AAMA), N -acety l-S-(2-
carbamoyl -2-hydroxyethyl) -1-cysteine (GAMA), 2 -hydroxybutenylmercapturic acid (2- MHBMA), 2 -OH-
Fluorene (2 -OH-Flu), 2 -Naphthol (2- OH-Nap),1 -OH-Phenanthrene (1 -OH-Phe), 3 -hydroxybenzo[a]pyrene (3-
OH-B[a]P), urine mutagenicity, 1- hydroxypyrene (1 -OH-Pyr). Blood:  carboxyhemoglobin (COHb)  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 7 of 51 Study Groups  
 Product Code  Product D escription  
Group 1  A Usual Brand Cigarette  
Group 2  B Mint on!® 2 mg  NP 
Group 3  C Mint on!® 4 mg  NP 
Group 4  D Mint on!® 8 mg  NP 
Group 5  - Tobacco Cessation Group  
Number of Subjects  
Approximately 150 subjects will be enrolled in the study. 
Diagnosis and Main Criteria for Inclusion Healthy males and females (no more than 60% of either gender), 21-65 years of age, with 
subjects aged 46 to 65 years being fully vaccinated for COVID-19 (SARS-CoV- 2) at leas t 14 
days before the screening visit. Subjects must be self -affirmed either menthol or non-menthol 
combustible cigarette smokers (average daily consumption between 10 and 30 factory-manufactured combustible cigarettes for at least 12 months prior to s creening).   
Study  Products  
• Product A (reference) : subject’s usual brand cigarette, ad libitum, from Day 1 to 
Day 7 
• Product B (test): 2 mg NP marketed as Mint on!
® 2 mg nicotine pouches, at least 
3 pouches/day, from Day 1 to Day 7 
• Product C (test): 4 mg NP marketed as Mint on!® 4 mg nicotine pouches , at least 
3 pouches/day, from Day 1 to Day 7 
• Product D (test): 8 mg NP marketed as Mint on!® 8 mg nicotine pouches , at least 
3 pouches/day, from Day 1 to Day 7 
Duration of Subject Participation in the Study  
Planned screening  duration: up to 28 days 
Planned study duration ( screening  to follow-up): approximately 5 weeks.  
  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 8 of 51 Endpoints  
Primary endpoint:  
• 24-hour total urinary NNAL (mg/24 hours) excreted on Day 7 
Secondary endpoints : 
• 24-hour urinary NE, 2-AN, 4-ABP , HEMA, CEMA , SPMA , HMPMA , 3-HPMA, 
2 HPMA, AAMA, GAMA, 2- MHBMA , 2-OH-Flu, 2-OH-Nap, 1-OH-Phe, 
3-OH- B[a]P , urine mutagenicity, and 1- OH-Pyr excreted on Day 7 
• COHb on Day 7 
• Product use behavior daily from Day 1 to Day 7 ( ie, number of cigarettes smoked per 
day[CPD], number of NP per day [NPPD], number of NP per use [NPPU], and 
average duration of each NP use) 
Safety:  
Adverse events, clinical l aboratory evaluations (hematology, clinical chemistry, urinalysis), 
12-lead electrocardiograms, vital signs measurements, and physical examinations. 
Statistical Methods  
Linear  mixed models for analysis of covariance will be used to compare the Day  7 biomar ker 
values between groups as described in the study objectives. In the statistical models, the 
outcome variable will be included as a dependent variable; group and gender will be included as fixed effects; and baseline values of corresponding biomarker will be included as 
covariates. For the NP groups compared to the continue cigarette smoking group, Dunnett’s 
method will be used for the adjustment of multiple comparisons. The SAS procedure Proc Mixed will be used. The least- squares means (LSM) difference and 95% confidence interval 
for the LSM difference between the test and reference groups and p-values will be provided.  
Product use behaviors and safety parameters will be analyzed using descriptive statistics.  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 9 of 51 TABLE OF CONTENTS  
TITLE PAGE  .............................................................................................................................1  
SPONSOR APPROVAL  ...........................................................................................................2  
INVESTIGATOR AGREEMENT .............................................................................................3  
STUDY IDENTI FICATION  .....................................................................................................4  
SYNOPSIS  .................................................................................................................................6  
TABLE OF CONTENTS  ...........................................................................................................9  
LIST OF TABLES A ND FIGURES ........................................................................................10  
LIST OF ABBREVIATIONS  ..................................................................................................12  
1. INTRODUCTION  ...........................................................................................................14  
1.1. Background ............................................................................................................14  
1.2. Study Rationa le ......................................................................................................15  
2. OBJECTIVES AND ENDPOINTS  .................................................................................16  
2.1. Objectives  ..............................................................................................................16  
2.2. Endpoints ...............................................................................................................16  
2.2.1.  Primary Endpoint .........................................................................................16  
2.2.2.  Secondary Endpoints ...................................................................................16  
3. INVESTIGATIONAL PLAN  ..........................................................................................17  
3.1. Overall Study Design and Plan ..............................................................................17  
3.2. Discussion of Study Design ...................................................................................18  
3.3. Selection of Study Products ...................................................................................19  
4. SELECTION OF STUDY POPULATION  .....................................................................19  
4.1. Inclusion Criteria  ...................................................................................................19  
4.2. Exclusion Criteria  ..................................................................................................20  
4.3. Subject Number and Identification ........................................................................22  
4.4. Subject Withdrawal and Replacement  ...................................................................22  
4.5. Study Termination .................................................................................................23  
5. STUDY PRODUCTS  ......................................................................................................23  
5.1. Description, Storage, Packaging, and Labeling .....................................................23  
5.2. Study Product Administration................................................................................24  
5.2.1.  Product Trial ................................................................................................24  
5.2.2.  Product Use from Day 1 ..............................................................................24  
5.3. Randomization .......................................................................................................25  
5.4. Blinding..................................................................................................................25  
5.5. Study Product Compliance ....................................................................................25  
5.6. Study Product Accountability, Storage, and Preparation.......................................25  
6. CONCOMITANT MEDICATIONS AND OTHER RESTRICTIONS  ..........................26  
6.1. Concomitant Medications ......................................................................................26  
6.2. Diet .........................................................................................................................27  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 10 of 51 6.3. Smoking .................................................................................................................27  
6.4. Exercise  ..................................................................................................................27  
7. STUDY ASSESSMENTS AND PROCEDURES  ...........................................................27  
7.1. Harmful and Potentially Harmful Constituent Assessments  .................................28  
7.1.1.  Carboxyhemoglobin Assessments ...............................................................28  
7.1.2.  Biomarkers of Exposure (other than COHb) Assessments ..........................28  
7.2. Product Use Behavior Assessments .......................................................................29  
7.3. Safety Assessments  ................................................................................................29  
7.3.1.  Adverse Events  ............................................................................................29  
7.3.2.  Clinical Laboratory Evaluations ..................................................................29  
7.3.3.  Vital Signs  ....................................................................................................30  
7.3.4.  12-Lead  Electrocardiogram .........................................................................30  
7.3.5.  Physical Examination ...................................................................................30  
7.3.6.  COVID-19 Screening...................................................................................31  
7.3.7.  Tobacco Cessation Information ...................................................................31  
8. DATA MANAGEMENT .................................................................................................31  
9. MONITORING OF THE STUDY...................................................................................32  
10. SAMPLE SIZE AND DATA ANALYSIS  ......................................................................32  
10.1.  Determination of Sample Size  ...............................................................................32  
10.2.  Analysis Populations ..............................................................................................33  
10.2.1.  Biomarker of Exposure Population ..............................................................33  
10.2.2.  Safety Population .........................................................................................33  
10.3.  Biomarker of Exposure Analyses ..........................................................................33  
10.4.  Product Use Behavior ............................................................................................33  
10.5.  Safety Analysis  ......................................................................................................33  
10.6.  Interi m Analysis  .....................................................................................................34  
11. REFERENCES  ................................................................................................................35  
12. APPENDICES  .................................................................................................................37  
Appendix 1: Adverse Event Reporting ..............................................................................38  
Appendix 2: Clinical Laboratory Evaluations ...................................................................42  
Appendix 3: Contraception Guidance ................................................................................43  
Appendix 4: Regulatory, Ethical, and Study Oversight Considerations ............................44  
Appendix 5: Schedule of Assessments ..............................................................................47  
Appendix 6: Fagerström Test for Cigarette Dependence14 Quest ionnaire ........................51  
 
LIST OF TABLES AND FIGURES  
Table 1:  Primary Endpoint .......................................................................................16  
Table 2:  Secondary Endpoints – Biomarkers of Exposure ......................................16  
Table 3:  Study Products ...........................................................................................24  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 11 of 51 Table 4:  Group Allocation .......................................................................................25  
 
Figure 1:  Study Schematic.........................................................................................18  
 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 12 of 51 LIST OF ABBREVIATIONS  
Abbreviation Definition  
AAMA  N-acetyl -S-(2-carbamoylethyl) cysteine  
4-ABP  4-aminobiphenyl  
AE adverse event  
ALCS  Altria Client Services  
2-AN 2-aminonaphthalene  
BOE  biomarker of exposure  
CC continue smoking cigarette s 
CEMA  cyanoethylmercapturic acid  
CFR  Code of Federal Regulations  
CLIA  Clinical Laboratory Improvement Amendments  
COHb  carboxyhemoglobin  
COVID  coronavirus disease  
CPD  number of cigarettes  smoked  per day  
CRO  contract research o rganization  
DMP  Data Management Plan  
ECG  electrocardiogram  
eCRF  electronic case report f orm 
EDC  electronic data capture  
EOS  end of study  
FDA  Food and Drug Administration  
FSH follicle -stimulating hormone  
GAMA  N-acetyl -S-(2-carbamoyl -2-hydroxy ethyl) -1-cysteine  
GCP  good clinical practice  
   
HEMA  2-hydroxyethyl mercapturic acid  
HPHC  harmful and potentially harmful constituents  
HMPMA  3-hydroxy -1-methylpropylmercapturic acid  
2-HPM A 2-hydroxypropylmercapturic acid  
3-HPMA  3-hydroxypropylmercapturic acid  
ICF informed consent f orm 
ICH International Council for /Conference on  Harmoni zation  
IRB institutional review b oard 
LSM  least-squares means  
MedDRA  Medical Dictionary for Regulatory Activities  
2-MHBMA  2-hydroxybutenylmercapturic acid  
MST  moist smokeless tobacco  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 13 of 51 NE nicotine equivalents  
NNAL  4-(methylnitrosamino) -1-(3-pyridyl) -1-butanol  
NP nicotine pouch  
NP2 2 mg  nicotine pouch  
NP4 4 mg  nicotine pouch  
NP8 8 mg  nicotine pouch  
NPPD  number of nicotine pouches used per day  
NPPU  number of nicotine pouch per use  
NT no tobacco  
3-OH-B[a]P  3-hydroxybenzo[a]pyrene  
2-OH-Flu 2-OH-Fluorene  
2-OH-Nap 2-Naphthol  
1-OH-Phe 1-OH-Phenanthrene  
1-OH-Pyr 1-hydroxypyrene  
OTDN  Oral Tobacco -Derived Nicotine  
PK pharmacokinetic  
QTcF  QT interval corrected for heart rate using Fridericia’s method  
SAE  serious adverse event  
SoA Schedule of A ssessments  
SPMA  S-phenylmercapturic acid  
UBC  usual brand cigarette  
  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 14 of 51 1. INTRODUCTION 
1.1. Background 
The harm caused by tobacco product use is primarily attributable to cigarette smoking. 
Smoking is the primary causal factor for at least 30% of all cancer deaths, for nearly 80% of deaths from chronic obstructive pulmonary disease, and early cardiovascular disease and deaths. The scientific evidence has clearly established that smoking cessation leads to a significant reduction in smoking- related morbidity and mortality.
 1,2,3,4 While cessation is the 
most desirable outcome for reducing the harm from smoking- related diseases, many adult 
smokers are unable or unwilling to quit. Public health authorities, including the FDA, have acknowledged a continuum of risk among tobacco products, with combustible cigarettes at the highest end and non-combustible products on the lower end of that spectrum.
5,6 
The Oral Tobacco -Derived Nicotine (OTDN) product s are non -combustible and intended for 
oral consumption. The OTDN category is one of the fastest  growing tobacco product 
segments in the United States.  
The on!® nicotine pouches (NPs) are one such portfolio of products that belong to the OTDN 
category. The on!® NP are innovative oral tobacco products that do not contain cut, ground, 
powdered, or leaf tobacco – a point of differentiation compared to smokeless tobacco products in the United States . The on!
® NP contain tobacco -derived nicotine and non- tobacco  
ingredients used in foods. The nicotine in the on!® products is extracted from tobacco plants 
and crystalized into nicotine salt. The on!® products do not contain any of the major food 
allergens (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, and soy). 
on!® product contains tobacco-derived nicotine, which is addictive. Nicotine can harm a baby 
for a female who is pregnant or nursing. Nicotine can increase heart rate, blood pressure and 
aggravate diabetes. Nicotine can cause dizziness, nausea and stomach pain. A burning sensation may be experienced while using oral nicotine products. on!
® product packages have 
the following warning: “WARNING: This product contains nicotine. Nicotine is an addictive chemical.”  
These products have been available since 2016. The on!
® NP are well tolerated and minimal 
consumer complaints have been reported. As an example of this, we received only 17 consum er reports in a 6-month timeframe, July through December 2019, during which time 
period 2,026,251 cans had been purchased . 
Two pharmacokinetic (PK) studies were conducted with  on!
® NP.  
The first study (ALCS- REG -19-12-OTDN) included 6 flavor variants (Berr y, Cinnamon, 
Citrus, Coffee, Original, and Wintergreen) of the 4 mg on! ® NP and the subject’s usual brand 
cigarette (UBC) as a reference product. The purpose of this PK study was to characterize the 
nicotine plasma PK profile from single use (1 pouch use for 30 minutes or 10 inhalations from 1 cigarette). Prior to randomization, subjects had a Product Trial period to use the NP at 
home for at least 3 days. In addition, s ubjects were allowed to use each of the NP ad libitum 
for 4 hours following randomization. A total of 42 (25 males, mean age 36.3 years) healthy 
adult cigarette smokers were enrolled and 41 completed the study. Starting from the first 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 15 of 51 product use in the Pr oduct Trial until the time of randomization, a total of 9 mild adverse 
events ( AEs) were reported by 6 (14%) subjects. The most frequent events were hiccups and 
throat irritation, experienced by 2 (5%) subjects each. The investigator considered 3 AE s 
(dyspepsia, pharyngeal paresthesia, and throat irritation) to be definitely related to study 
product, 2 AE s (hiccups and throat irritation) to be likely related, 2 AE s (hiccups and 
productive cough) to be possibly related, and the remaining 2 AE s (headache and toothache) 
not related. Of note, the investigator was unable to determine whether the AEs were related to 
NP or cigarette since both products were allowed ad libitum during the Product Trial. From 
randomization on Day -1 through study completion on Day 7, a total of 25 mild AEs were reported by 18 (43%) subjects, with more subjects experiencing AEs following cigarettes (8 [19%]) compared to NP (≤ 3 [7%] subjects across flavors). Pain in extremity (due to 
venipunctures/blood draws) was the most frequently reported event, experienced by 4 (10%) subjects. All remaining AEs were reported by 3 or fewer (≤ 7%) subjects each. The 
investigator considered 3 AE s (dizziness [cigarette], gingival bleeding [Cinnamon NP ], and 
hyperhidrosis [cigarette]) to be likely related to study product, 3 AE s (1 dyspepsia [Citrus 
NP] and 2 headaches [cigarette]) to be possibly related, and the remaining events unlikely 
related or not related.  There were no serious AEs  (SAEs ) reported in this study and no 
subjects were discontinued due to AEs. 
The second study ( ALCS -REG -19-13-OTDN) included 5 levels (1.5, 2. 3.5, 4, and 8 mg) of 
Mint on!
 ® NP. A total of 30 (29 males, mean age 34.9 years) healthy adult dual tobacco users 
(those who smoke cigarette and also use moist smokeless tobacco [MST]) were enrolled and 
completed the study with the similar design as the first study. During the Product Trial 
period, during which subjects were allowed to use ad libitum the supplied Mint on! ® NP, and 
their usual brands of combustible cigarettes and loose MST, a total of 9 mild AEs were reported by 6 (20%) subjects. The most frequent event was headache, experienced by 4 (13%) subjects. The investigator considered all events unlikely or not related to study product. From the time of randomization on Day -1 until the end of study on Day 7, a total of 61 AEs were reported by 20 (67%) subjects across study products. The majority of the events (59) were mild in severity and 2 (headache [cigarette] and nausea [8 mg NP ]) were moderate. 
Headache was the most frequently reported event, experienced by 8 (27%) subjects, followed 
by nausea, experienced by 6 (20%) subjects. All remaining events were reported by 4 or 
fewer (≤ 13%) subjects each. The investigator considered 7 events to be likely related to 
study product and 13 events possibly related. The likely/possibly related events occurred across study products and included, but were not limited to, nausea, vomiting, dizziness, and headache. The remaining 41 events were considered unlikely/not related to study product. 
There were no SAEs reported in this study and no subjects were discontinued due to AEs. 
1.2. Study Rationale 
A dose-response relationship has been demonstrated between cigarette smoking and cancer of 
the lung, larynx, oral cavity, and urinary bladder (2004 SGR Report – The Health Consequences of Smoking
7). Therefore, sustained and prolonged reduction in exposure to the 
harmful and potentially harmful constituents (HPHCs) from cigarette smoke will result in reduction in smoking- related disease risks. The exposure can be assessed by measuring the 
levels of constituents or metabolites in urine or blood (biomarkers of exposure - BOE s). 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 16 of 51 The purpose of this study is to generate evidence regarding the extent of reduction in 
exposure to select ed HPHCs in adult smokers switching to on!® NPs. The study intends to 
determine changes in exposure to selected HPHC s by measuring biomarkers in adult smokers 
who completely switch from smoking to use of on!® NP compared to those who continue 
smoking cigarettes (CC) or stop using all tobacco products (NT).  
2. OBJECTIVES AND ENDPOINTS  
2.1. Objectives 
The primary objective of the study is: 
• To compare 24-hour urinary total 4- (methylnitrosamino) -1-(3-pyridyl)-1-butanol 
(NNAL) in subjects using NP for 7 days versus subjects who continue to smoke 
cigarettes for 7 days.  
The secondary objectives of the study are: 
• To compare BOEs (except total NNAL) in subjects using NP  for 7 days versus 
subjects who continue to smoke cigarettes for 7 days 
• To compare BOEs in subjects using NP  for 7 days versus subjects who stopped using 
any tobacco products for 7 days 
• To characterize product use behaviors (such as: number of cigarettes smoked per day  
[CPD], number of NPs use d per day  [NPPD] , number of NPs per use [NPPU], 
average duration of each NP  use).  
2.2. Endpoints  
2.2.1. Primary Endpoint  
The primary en dpoint is presented in Table 1. 
Table 1: Primary Endpoint  
2.2.2. Secondary Endpoints  
The secondary BOE endpoints are presented in Table 2. 
Table 2: Secondary Endpoints – Biomarkers of Exposure 
Biomarker of Exposure  Abbreviation  Associated Toxicant  Matrix  
Nicotine equivalents (nicotine, 
cotinine, 3 -hydroxycotinine and 
their glucuronide conjugates)  NE Nicotine  Urine (24  hours)  Biomarker  Abbreviation  Associated Toxicant  Matrix  
Total 4 -(methylnitrosamino) -
1-(3-pyridyl) -1-butanol  NNAL  4-[Methyl(nitroso)amino] -1-(3-
pyridinyl) -1-butanone  
 Urine (24 -hour)  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 17 of 51 Biomarker of Exposure  Abbreviation  Associated Toxicant  Matrix  
3-hydroxypropylmercapturic acid 3-HPMA  Acrolein  Urine (24  hours)  
3-hydroxy-1-
methylpropylmercapturic acid HMPMA  Crotonaldehyde  Urine (24  hours)  
2-hydroxypropylmercapturic acid  2-HPMA  Propylene oxide  Urine (24  hours) 
S-phenylmercapturic acid SPMA  Benzene  Urine (24  hours)  
cyanoethylmercapturic acid  CEMA Acrylonitrile  Urine (24  hours)  
1-hydroxypyrene  1-OH-Pyr Pyrene  Urine (24  hours)  
2-hydroxyethylmercapturic acid  HEMA Ethylene oxide  Urine (24  hours)  
2-hydroxybutenylmercapturic acid  2-MHBMA  1,3 butadiene  Urine (24  hours) 
2-Naphthol  2-OH-Nap Naphthalene  Urine (24  hours) 
4-aminobiphenyl  4-ABP  4-aminobiphenyl  Urine (24  hours)  
2-aminonaphthalene  2-AN 2-aminonaphthalene  Urine (24  hours)  
N-acetyl -S-(2-carbamoylethyl) 
cysteine  AAMA  Acrylamide  Urine (24  hours) 
N-acetyl -S-(2-carbamoyl -2-
hydroxy ethyl) -1-cysteine  GAMA  Acrylamide  Urine (24  hours) 
2-OH-Fluorene  2-OH-Flu Fluorene  Urine (24  hours) 
1-OH-Phenanthrene  1-OH-Phe Phenanthrene  Urine (24  hours) 
3-hydroxybenzo [a]pyrene  3-OH-B[a]P  Benzo -a-pyrene  Urine (24  hours) 
Urine mutagenicity  - - Urine (24  hours) 
Carboxyhemoglobin  COHb Carbon monoxide  Blood  
Additional endpoint is : 
• Product use behavior daily from Day 1 to Day 7 ( ie, CPD, NPPD, NPPU,  and the 
average duration of each NP use). 
3. INVESTIGATIONAL PLAN 
3.1. Overall Study Design and Plan  
This will be an open-label, randomized, 5 parallel-groups clinical study evaluating changes in 
exposure to selected HPHCs and product use behavior in adult smokers.  
Study population will be randomized into  5 groups: 
• Group 1 (n = 30): CC; subjects will be asked to continue smoking their UBCs ad 
libitum for 7 days. 
• Group 2 (n = 30): 2 mg NP (NP2); subjects will exclusively use 2 mg NP, using at 
least 3 pouches per day for 7 days. 
• Group 3 (n = 30): 4 mg NP (NP4); subjects will exclusively use 4 mg NP, using at 
least 3 pouches per day for 7 days. 
• Group 4 (n = 30): 8 mg NP (NP8); subjects will exclusively use 8 mg NP, using at 
least 3 pouches per day for 7 days. 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 18 of 51 • Group 5 (n = 30): No Tobacco (NT); subjects will completely stop all tobacco product 
usage for 7 days. 
The goal is to recruit approximately 150 subjects (not more than 60% of either gender) with the aim of at least 100 subjects completing the study (20 subjects , minimum per group).  
An overview of the study design is shown in Figure 1. 
Figure 1:  Study Schematic  
 
ɫ Randomization is expected to occur on Day 1, however, in order to make study product preparation for Day 1 
easier and more manageable for the site, randomization of study subjects will also be allowed after 19:00 on  
Day  -1. 
Abbreviations: EOS = end of th e study; NP2 = 2 mg  nicotine pouches; NP4 = 4 mg nicotine pouches; NP8 = 8 
mg nicotine pouches; NT = no tobacco; UBC = usual  brand cigarette. 
Potential subjects will be screened to assess their eligibility to enter the study within 28 days 
prior to the fir st product administration. Subjects will be admitted into the study site on 
Day -3 and be confined to the study site until discharge on Day 8.  
The total duration of study participation for each subject (from s creening  through last  visit) is 
anticipated to be approximately 5 weeks.  
The start of the study is defined as the date the first  subject  signs an informed consent f orm 
(ICF). The point of enrollment occurs at the time of subject check -in visit. The study 
completion  is defined as the date of the last subject’s last assessment (scheduled or 
unscheduled).  A Schedule of Assessments (SoA) is presented in Appendix 5. 
3.2. Discussion of Study Design  
This is an open- label, randomized, 5 parallel -group clinical study evaluating changes in 
exposure to selected HPHCs and product use behavior in adult smokers.  Study population will be divided in to 5 groups (see  Section  3.1 for details). Group 1 (subjects 
continuing to smoke their UBC ) and Group 5 ( NT) will serve as references, indicating 
maximum and minimum levels of BOEs.  
Collecting CPD, NPPD, NPPU, and the average duration of each NP use will help to define 
use behaviors.  

Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 19 of 51 This study follows the recommendations of the Modified Risk Tobacco Product Applications 
draft FDA guidance.8 
3.3. Selection of Study  Products   
on!® Nicotine pouches are available in 5 levels  (1.5, 2, 3.5, 4, and 8 mg) of nicotine . The 2 -, 
4-, and 8-mg levels  will be assessed in this study  as they represent the range of nicotine levels 
across the portfolio. The Mint flavor was chosen as it is the most widely used flavor variant. Subjects will be required to use NP at least 3 times per day, to ensure a minimum use of the 
product. 
4.  SELECTION OF STUDY POPULATION  
Self-affirmed adult smokers will be screened to enroll approximately 150 subjects (not more 
than 60% of either gender). Study population will be divided into  5 groups: 
• Group 1 (n = 30): CC; subjects will be asked to continue smoking their UBCs ad 
libitum for 7 days. 
• Group 2 (n = 30): 2 mg NP (NP2); subjects will exclusively  use 2 mg NP, using at 
least 3 pouches per day for 7 days. 
• Group 3 (n = 30): 4 mg NP (NP4); subjects will exclusive ly use 4 mg NP, using at 
least 3 pouches per day for 7 days. 
• Group 4 (n = 30): 8 mg NP (NP8); subjects will exclusively  use 8 mg NP, using at 
least 3 pouches per day for 7 days. 
• Group 5 (n = 30): NT ; subjects will completely stop all tobacco product usage for 
7 days. 
4.1. Inclusion Criteria  
Subjects must satisfy all of the following criteria  at the screening  visit unless otherwise 
stated : 
1. Voluntary consent to participate in this study documented on the signed ICF 
2.  
3. Smoking history (self -reported at s creening) of an average of at least 10 but no more 
than 30 factory- manufactured combustible cigarettes (either menthol or non-menthol) 
daily for at least 12 months prior to screening. Brief periods ( ie, up to 7 consecutive 
days) of non-smoking during the 3 months prior to s creening (eg , due to illness or 
participation  in a study where smoking was prohibited) will be permitted 
4. Positive urine cotini ne (≥ 500 ng/mL) at screening  
5. Female subjects (see Appendix 3) who are heterosexually active and of childbearing 
potential ( eg, neither surgically sterile at least 6 months prior to check -in nor 
postmenopausal with amenorrhea for at least 12 months  prior to c heck -in with 
follicle -stimulating hormone [ FSH] levels consi stent with postmenopausal status) 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 20 of 51 must have been using one of the following forms of contraception for the time period 
indicated and agree to continue using it through completion of the study: 
o Hormonal ( eg, oral, vaginal ring, transdermal patch, implant, injection) 
consistently for at least 3 months prior to c heck -in, double barrier ( ie, condom 
with spermicide or diaphragm with spermicide)  consistently for at least 
4 weeks prior to c heck -in, an intrauterine device for at least 4 months prior to 
check -in 
o Exclusive partner who has been vasectomized for at least 6 months (inclusive) prior to c heck -in 
Female subjects of childbearing potential who are not currently engaging in heterosexual intercourse must agree to use one of the above methods of birth control through completion of study, in the event that they have heterosexual intercourse during the course of the study. 
6. Female subjects who are of nonchildbearing potential must have undergone one of the following sterilization procedures at least 6 months prior to c heck -in: 
o Hysteroscopic sterilization (including Essure
® or similar nonsurgical 
sterilization procedures); bilateral tubal ligation or bilateral salpingectomy; hysterectomy; bilateral oophorectomy 
Or be postmenopausal with amenorrhea for at least 12 months prior to c heck -in and 
have FSH levels consistent with postmenopausal status 
7. Willing to comply with the requirements of the study 
8. Willing to use all 3 on!
® NP after  the Product Trial at check -in 
9. Willing and able to abstain from cigarettes from Day 1  through the end of the study 
(EOS)  
10. Healthy adult males and females, 21 to 65 years of age, inclusive at screening, with subjects aged 46 to 65 years being fully vaccinated for COVID-19 (SARS-CoV- 2) at 
least 14 days before  the screening visit. 
4.2. Exclusion Cr iteria  
Subjects will be excluded from the study if there is evidence of any of the following criteria at screening, c heck -in, or prior to randomization, as appropriate. 
1. Use of any type of tobacco- or nicotine-containing products other than manufactured cigarettes (eg , e-vapor products, roll-your-own cigarettes, bidis, snuff, nicotine 
inhaler, pipe, cigar, chewing tobacco, nicotine patch, nicotine spray, nicotine lozenge, or nicotine gum) in the 7 days prior to c heck -in 
2. Self-reported puffers ( ie, adult smokers who draw smoke from the cigarette into the 
mouth and throat but do not inhale) 
3. Planning to quit smoking in the next 30 days (from screening visit) 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 21 of 51 4. History or presence of clinically significant gastrointestinal, renal, hepatic, 
neurologic, hematologic, endocrine, oncologic, urologic, existing respiratory diseases, immunologic, psychiatric, lymphatic, or cardiovascular disease, or any other condition that, in the opinion of the investigator, would jeopardize the safety of the subject or imp act the validity of the study results 
5. Clinically significant abnormal findings on the vital signs, physical examination, medical history, electrocardiogram  (ECG ), or clinical laboratory results, in the 
opinion of the investigator 
6. Positive test for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus at screening  
7. History or presence of any type of malignant tumors 
8. Current evidence or any history of congestive heart failure 
9. Diabetes mellitus (fasting glucose ≥126 mg/L [7 mmol/L]) that is not controlled by diet/exercise alone, in the opinion of the investigator 
10. An acute illness (eg , upper respiratory infection, viral infection) requiring treatment 
with prescribed medicines within 2 weeks prior to c heck -in 
11. Dentition that prevents subjects from using on!
® NP products 
12. Allergic to or cannot tolerate mint flavoring agents or phenylalanine 
13. Any planned surgery from the time of screening through EOS  
14. History of drug or alcohol abuse within 24 months prior to c heck -in 
15. Fever ( ie, body temp erature >100.5°F) at screening or c heck -in. One recheck may be 
performed at the investigator’s discretion  
16. Body mass index greater than 40.0 kg/m2 or less than 18.0 kg/m2 at screening  
17. Systolic blood pressure >150 mmHg and/or diastolic blood pressure > 90 mm Hg at 
screening or c heck -in, measured after being seated for at least 5 minutes. One recheck 
may be performed at the investigator ’s discretion  
18. Estimated creatinine clearance (by Cockcroft -Gault equation) < 80 mL/minute at 
screening  
19. Serum alanine aminotrans ferase ≥ 1.5 times the upper limit of normal and/or aspartate 
aminotransferase ≥ 1.5 times the upper limit of normal at screening  
20. Positive screen for alcohol (breath) or any of the following drugs of abuse (urine), regardless of the reason of use: amphetamines, methamphetamines, opiates, cannabinoids, or cocaine at screening or c heck -in 
21. Female subjects who are pregnant (positive serum pregnancy test at screening or urine 
pregnancy test at check -in), lactating, or intend to become pregnant from screening 
through EOS  
22. Use of prescription or over-the-counter bronchodilator medication ( eg, inhaled or oral 
ß-agonists) within 12 months prior to c heck -in 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 22 of 51 23. Use of medications or foods known or are suspected to interact with cytochrome P450 
2A6 (including, but not limited to, amiodarone, amlodipine, amobarbital, buprenorphine, clofibrate, clotrimazole, desipramine, disulfiram, entacapone, fenofibrate, isoniazid, grapefruit, ketoconazole, letrozole, methimazole, methoxsalen, metyrapone, miconazole, modafinil, orphenadrine, pentobarbital, phenobarbital, pilocarpine, primidone, propoxyphene, quinidine, rifampicin, rifampin, secobarbital, selegiline, s ulconazole, tioconazole, tranylcypromine) within 14 days or 5 half- lives 
of the drug, whichever is longer, prior to c heck -in or during the study 
24. Use of antibiotic treatment within 2 weeks prior to check -in 
25. Plasma donation within 7 days prior to c heck -in 
26. Donation of blood or blood products (with the exception of plasma as noted above), 
had significant blood loss, or received whole blood or a blood product transfusion within 56 days prior to c heck -in 
27. Participation in a previous clinical study for an investigational drug, device, biologic, or a tobacco product within 30 days prior to c heck -in 
28. Participation in 2 or more Altria Client Services ( ALCS ) studies within the past 
12-month period prior to c heck -in 
29. Subject or a first -degree relative ( ie, parent, sibling, child, spouse/partner) is a current 
or former employee of the tobacco industry or a named party or class representative in litigation with any tobacco company 
30. Subject or a first -degree relative ( ie, parent, sibling, child, spouse/partner) is a cur rent 
employee of the study site 
31. Positive result for coronavirus disease ( COVID )-19 (SARS -CoV-2) test at screening 
or check -in 
32. One or more “yes” answers  to any of the questions on the COVID-19 (SARS -CoV-2) 
screening questionnaire (provided by the study site ) at screening or c heck -in.  
33. Have been diagnosed with major depressive disorder or have a history of suicide attempt.   
4.3. Subject Number and Identification 
Subjects will be assigned a unique subject identification number upon signing informed consent. 
Subjects will be identified by subject number on all study documentation.  4.4. Subject Withdrawal and Replacement  
A subject is free to withdraw from the study at any time. In addition, a subject will be 
withdrawn  from the study if any of the following criteria are met:  
• Change in compliance with any inclusion/exclusion criterion that is clinically relevant 
and affects subject safety  as determined by the investigator  (or designee) 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 23 of 51 • Noncompliance with the study restrictions that might affect subject safety or study 
assessments/objectives, as considered applicable by the investigator (or designee) 
• Any clinically relevant sign or symptom that, in the opinion of the investigator (or 
designee) , warrants subject withdrawal . 
If a subject is withdrawn from product use, the sponsor will be notified and the date and 
reason(s) for the withdrawal will be documented in the subject’ s electronic case report f orm 
(eCRF). If a subject is withdrawn from  the study, efforts will be made to perform  all EOS  
assessments, if possible ( Appendix 5). Other procedures may be performed at  the 
investigator ’s (or designee’s) and/or sponsor ’s discretion. If the subject is in -house, these 
procedures should be performed before the subject is discharged from the clinic. The 
investigator (or designee) may also request that the subject return for an additional follow-up 
visit. All withdrawn subjects will be followed until resolution of all their AEs or until the unresolved AEs are judged by the investigator (or designee) to have stabilized.  
Subjects withdrawing from the study may be replaced at the discretion of the sponsor. Subjects enrolled in the Product Trial but who failed at check -in or dropped prior to 
randomization may be replaced without consultation of the sponsor. Subjects completing, withdrawing, or who are removed from this study cannot re- enter.  
4.5. Study Termination  
The study may be discontinued at the discretion of the in vestigator (or designee) , sponsor , or 
sponsor ’s medical monitor if any of the following criteria are met:  
• Adverse event s unknown to date (ie, not previously reported in any similar study on 
the study products with respect to their nature, severity, and/or duration) 
• Increased frequency , severity , and/or duration of known, anticipated, or previously 
reported AEs (this may also apply to AEs defined at c heck -in as baseline signs and 
symptoms) 
• Medical or ethical re asons affecting the continued performance of the study  
• Difficulties in the recruitment of subjects  
• Other administrative reasons . 
5. STUDY PRODUCT S 
5.1. Description, Storage, Packaging, and Label ing 
Study products will be supplied by the sponsor (or designee), along with the batch/lot numbers and certificates of analysis.  
Details on study products can  be found in Table 3. 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 24 of 51 Table 3: Study Products  
Study 
Product  Product 
Code  Format  Product  Nicotine 
Yield/Content  
1 B Pouch  Mint on!® 2 mg  nicotine pouches  2 mg /pouch  
2 C Pouch  Mint on!® 4 mg  nicotine pouches  4 mg /pouch  
3 D Pouch  Mint on!® 8 mg  nicotine pouches  8 mg /pouch  
The study products will be packaged in the original commercial  packs in sealed pre-
packaging. Each product pack contains 20 pouches. To open the packages, the sealed 
pre-packaging will have to be broken and the lid opened .  
Study products will be stored at the study site in a location that is locked with restricted access.  
The study product containers will be labeled in accordance with applicable laws and 
regulations.  
5.2. Study Product  Administration  
5.2.1. Product Trial  
At Day -3, subjects will engage in a brief Product Trial  using 1 Mint on!
® 8 mg NP  for 
10 minutes to allow them to become accustomed to the product and to confirm their  ability to 
tolerate the study product. Subjects will be instructed to place the pouch between the upper 
lip and gum, on either side of the mouth, per subject’s choice. Subjects will be informed that 
these products are spit- free. 
5.2.2. Product Use from Day 1  
Subjects will begin using the assigned study products or completely stop using tobacco products on the morning of Day 1 and continue through Day 7 according to the randomization: 
• Subjects in Group 1 will be allowed to smoke their UBCs ad libitum (ie , no re striction 
on the duration of use or the number of CPD ) from 07:00 through 23:00. Subjects will 
be allowed to smoke upon request to the clinic staff but will only be allowed 1 cigarette at a time.  
• Subjects in Groups 2, 3, and 4 will use the assigned NPs ad libitum (ie , no restrictions 
on the NPPU , the NPPD , or the duration of use) except for 3 specific NP use 
opportunities at approximately 11:00, 15:00, and 19:00 each day during which subjects will be asked to keep the assigned NP in their mouth for at least 10 minutes. Subjects will be allowed to use the NPs upon request.  
• Subjects in Group 5 will not be allowed to smoke or use NPs. 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 25 of 51 Study product use will not be permitted from 23:00 to 07:00 each day during the study from 
check -in (Day -3) until Day 7. Study products and  cigarettes will not be allowed on Day 8 
(discharge day ). 
5.3. Randomization 
On Day 1, the subjects will be randomized to 1 of the following 5 groups in a 1:1:1:1:1 ratio, with not more than 60% of either gender. Subjects will be stratified by gender and screening 
visit self-reported CPD  (≤16; >1 6). Randomization is expected to occur on Day 1, however, 
in order to make study product preparation for Day 1 easier and more manageable for the site, randomization of study subjects will also be allowed after 19:00 on Day -1. 
Table 4: Group Allocation 
Group number  Study Product  Number of subjects  
Group 1  UBC (CC)  30 
Group 2  2 mg  NP (NP2)  30 
Group 3  4 mg  NP (NP4)  30 
Group 4  8 mg  NP (NP8)  30 
Group 5  No Tobacco (NT)  30 
5.4. Blinding  
This is an open-label study. 5.5. Study Product Compliance  
For study integrity, all smoked cigarette butts and all used NPs will be collected throughout 
the study ( from Day -3 to Day 7).  
The following measures will be employed to ensure study product use compliance:  
• Subjects from Group 1 will request a cigarette from  the clinic staff, each time they 
want to smoke a cigarette . They will be instructed to return each cigarette butt upon 
compl etion . Only 1 cigarette will be dispensed for use at a time and subjects will be 
instructed to return the cigarette butt before being allowed to obtain another UBC 
• Subjects from Groups 2, 3, and 4 will request NPs from  the clinic staff, each time they 
want to use a NP. At approximately 11:00, 15:00, and 19:00, they will use their 
assigned NP in the presence of a clinical staff member. Subjects will be instructed to 
return each used NP upon completion. 
5.6. Study Product Accou ntability , Storage, and Preparation 
All study products will be provided by the sponsor , except UBCs . The study staff at the site 
will coordinate shipping of the study products from the sponsor. The study staff will document the date each shipment was received and record  it in the inventory records. The 
study staff will document and reconcile the total number of products shipped to the site, the total number of study products used during the study, and the total number of unused study 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 26 of 51 products remaining at the EOS . The site pharmacy will retain and store 2 cans/packages of 
each study product at the site until finalization of the final study report. 
All subjects will be required to provide a sufficient supply of their UBC to the study site for 
use from check -in through Day 7 (10 days) in case they are randomized to continue smoking 
their UBC. This supply will be calculated from the number of CPD repor ted at screening plus 
an additional 20% rounded up to the next pack. For example, a subject reporting to smoke 15 CPD  would bring 9 packs (15 CPD  x 10 days = 150 cigarettes + an additional 30 
cigarettes = 180 cigarettes total [9 packs]). The clinical site will purchase additional cigarettes 
if subjects run out of cigarettes during the study. 
All study products will be stored in a locked, limited- access area at  the study site and kept at 
controlled room temperature (defined as 15°C – 25 °C [59 °F – 77°F], with excursions 
permitted to 30 °C [86 °F]). A sufficient supply for each subject may be transferred and kept in 
a secure area in the clinic (eg , locked drawer or cupboard) each day as necessary, with 
appropriate documentation of transfer noted as above. Any unused packs of cigarettes will be returned to the study subjects upon their completion 
or withdrawal from the study. 6. CONCOMITANT MEDICATIONS  AND OTHER RESTRICT IONS  
6.1. Concomitant Medications  
Any medications, and the reason for its use, taken from 30 days prior to c heck -in through 
check -in will be recorded  as prior medications. 
Any concomitant medications, and the reason for its use, taken from c heck -in through the 
EOS (or upon early termination) will be recorded as concomitant medication. Prohibited medications are included in the exclusion criteria ( Section  4.2).  
Stable doses ( ie, no dosage adjustments within 30 days prior to c heck -in) of prescription or 
over-the-counter medications required to treat an investigator-approved disease or condition 
are permitted at the discretion of the investigator. Hormonal contraceptives ( eg, oral, vaginal 
ring, transdermal patch, implant, injection) and hormonal replacement therapy are permitted. Use of over-the- counter analgesics (eg, acet aminophen, ibuprofen), m ilk-of-m agnesia, 
antihistamines, and nasal decongestants are permitted as needed to treat AEs experienced by subjects , at the discretion of the investigator. Note that some decongestants might cause a 
positive urine/saliva drug screen result and therefore their use should be discouraged within 5 to 7 days of those tests.  
The administration of any other concomitant medications during the study is prohibited 
without prior approval of the investigator (or designee), unless its use is deemed necessary for the treatment of an AE.  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 27 of 51 6.2. Diet 
While confined at the study site, subjects will receive a standardized diet at scheduled times 
that do not conflict with other study- related activities.  
No foods or beverages containing alcohol will be allowed for 48 hours prior to screening, 
check -in, and during confinement at the study site . 
Consumption of broiled or pan- fried meat, pre- cooked meats (eg , tuna, ham, corned beef, 
smoked lunchmeats), bacon, or sausage will not be allowed for 48 hours prior to c heck -in and 
during the confinement at the study site. Every attempt will be made to ensure  that food 
provided to a subject on Day -2 is similar to what is provided to that subject on Day 6 and the food provided to a subject on Day -1 is similar to what is provided to that subject on Day 7. 
Caffeinated beverages (up to 1 cup per meal) may be ser ved while subjects are confined at 
the study site. 
Subjects will be  fasted overnight ( at least  8 hours) before collection of blood samples for 
clinical laboratory evaluations. 6.3. Smoking  
Following Product Trial on Day -3, subjects will continue to smoke their UBC through 23:00 
on Day -3 and from 07:00 to 23:00 on Days -2 and -1.  Subjects from Groups 2, 3, 4, and 5 will not be allowed to smoke from Day 1 to the EOS  
Smoking will be limited to a designated area of the clinic. Subjects permitted to smoke 
(Group 1) will be housed separately from the subjects from Groups 2, 3, 4, and 5.  
Any illicit use of any tobacco- or nicotine-containing products or sharing of study products 
will be strictly prohibited and will be  grounds for immediate termination from the study at the 
discretion of the investigator. 
6.4. Exercise  
Strenuous exercise will be forbidden for 48 hours prior to c heck -in and while the subject is 
confined at the study site. 
7. STUDY ASSESSMENTS AND PROCEDURES  
Every effort will be made to schedule and perform the procedures as closely as possible to the 
nominal time, giving considerations to appropriate posture conditions, practical restrictions, and the other procedures to be performed at the same timepoint. 
The highest priority procedures will be performed closest to the nominal time. The order of 
priority for scheduling procedures around a timepoint is (in descending order of priority): 
• 24-hour urine sampling 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 28 of 51 • Vital signs  
• ECG  
• Physical examination  including an oral exam 
• Blood samples . 
7.1. Harmful and Potentially Harmful Constituent Assessment s 
7.1.1. Carboxyhemoglobin A ssessment s 
7.1.1.1.  Blood Sample Collection and Processing  
Blood samples will be collected by venipuncture or cannulation at the times indic ated in the 
SoA in  Appendix 5.  
Procedures for collection, processing, and shipping of blood samples will be detailed in a 
separate document .  
The maximum blood volume for the entire study, including samples taken for safety evaluation, will not exceed 450 mL.  
7.1.1.2.  Analytical Methodology 
Blood concentrations of COHb  will be determined using  a validated analytical procedure. 
Specifics of the analytical method  will be provided in a separate document.  
7.1.2. Biomarkers of Exposure (o ther than COHb) A ssessment s 
Biomarkers of exposure other than COHb (see list in Table 1 and  Table 2) will be assessed in 
24-hour urine. 
7.1.2.1.  Urine Sample Collection and Processing  
A 24-hour urine collection will be performed at the times indicated in the SoA in Appendix 5.  
All urine voids over a 24-hour period (24-hour urine) will be collected for BOE analysis. The 24-hour urine collection begins on each scheduled day after the first morning void and any void prior to 07:00, and finishes the following morning with the last void collected at approximately 07:00 (including first morning void).  
Unused urine samples will be frozen and may be used for additional biomarkers of exposure 
assessments for up to 3 years. 
Procedures for collection, processing, and shipping of uri ne samples will be detailed in a 
separate document.  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 29 of 51 7.1.2.2.  Analytical Methodology 
Urine concentrations of BOEs  will be determined using validated analytical procedures. 
Specifics of the analytical method s will be provided in a separate document.  
Urine creatinine will be measured in each 24 -hour collection and may be used to adjust the 
concentration values of urine BOEs.  
7.2. Product Use Behavior Assessments  
The following parameters will be collected to assess product use behavior: 
• Number of CPD: number of cigarettes smoked from 07:00 to 23:00, each day 
• NPPD: number of NP used from 07:00 to 23:00, each day 
• NPPU : number of NPs that could be used at once will not be limited 
• Average duration of each NP use: time of NP placement in the subject’s  mouth and 
time it was removed from the subject’s  mouth.  
7.3. Safety Assessments 
7.3.1. Adverse Events  
Adverse event definitions, assignment of severity and causality, and procedures for reporting 
SAEs are detailed in  Appendix 1. 
The condition of each subject will be monitored from the time of signing the ICF  to final 
discharge from the study.  
Subjects will be observed for any signs or symptoms and asked about their condition by open 
questioning, such as “How have you been feeling since you were last asked?”, at least once each day while resident at the study  site and at each study visit. Subjects will also be 
encouraged to spontaneously report AEs occurring at any other time during the study. 
All nonserious AEs, whether reported by the subject voluntarily or upon questioning, or 
noted on physical examination, will be recorded from initiation of study product until study completion. Serious AEs will be recorded from the time the subject signs the ICF until study completion. The nature, time of onset, duration, and severity will be documented, together with an investigator ’s (or designee’s) opinion of the relationship to the use of the study 
product. 
Adverse events recorded  during the course of the study will be  followed up, where possible, 
to resolution or until the unresolved AEs are judged by the investigator (or designee) to have 
stabilized. This will be completed at the investigator ’s (or designee’s) discretion. 
7.3.2. Clinical Laboratory Evaluations 
Blood and urine samples will be collected for c linical laboratory evaluations  at the times 
indicated in the SoA in Appendix 5. Clinical laboratory evaluations are listed in Appendix 2.  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 30 of 51 Subjects will be asked to provide urine samples for drugs of abuse screen and cotinine test 
and will undergo an alcohol breath test  at the times indicated in the SoA in Appendix 5. For 
female subjects, a pregnancy test will be performed at the times indicated in the SoA in 
Appendix 5.  
All clinical laboratory tests will be conducted by a laboratory accredited by Centers for 
Medicare and Medicaid Services (Clin ical Laboratory Improvement Amendments [CLIA] of 
1988) or at the clinic al study site using CLIA-waived kits or procedures.  
An investigator (or designee) will perform a clinical assessment of all clinical laboratory data.  
Values for the laboratory paramete rs are to be within the laboratory normal ranges or deemed 
not clinically significant in the opinion of the investigator (or designee) or otherwise meet the specified values (ranges) in the protocol. One recheck may be performed at the investigator’s discr etion for all clinical laboratory tests except for the urine/saliva drug screen, urine/breath 
alcohol screen, and urine cotinine test.  
7.3.3. Vital Signs  
Seated blood pressure, seated heart  rate, seated respiratory rate, and oral body temperature 
will be assessed at the times indicated in the SoA in Appendix 5. Vital signs may also be 
performed at other times if judged to be clinically appropriate. All measurements will be performed singly and repeated once if outside the relevant clinical 
reference range.  
Subjects must be seated for at least 5  minutes before blood pressure, heart  rate, and 
respiratory rate measurements.  
Product use is to be stopped 15 minutes prior to vital sign measurement. 7.3.4. 12-L ead Electrocardiogram  
Resting 12- lead ECGs  will be recorded after the subject has been supine and at rest for at 
least 5  minutes and at least 15 minutes after the last nicotine containing product used. The 
ECGs will be performed  at the times indicated in  the SoA in Appendix 5. The ECGs will be 
documented by the investigator or his/her medically qualified designee as normal, having a 
clinically insignificant abnormality, or having a clinically significant abnormality.  
Additional 12-lead ECGs may be performed at other times if judged to be clinically appropriate. The investigator  (or designee)  will perform a clinical assessment of each 12 -lead 
ECG.  
 
7.3.5. Physical Examination 
A general physical examination with o bservations and questioning by the investigator or 
his/her medically qualified designee will be performed at screening. All physical 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 31 of 51 examinations will include, at a minimum, assessment of the following systems: skin, head, 
ears, eyes, nose and throat (including oral cavity and oropharynx), respiratory system, cardiovascular system, gastrointestinal system, blood and lymphatic systems, and the musculoskeletal system.  Symptom- directed physical examination will be performed at the 
other timepoints specified in  the SoA ( Appendix 5).  
7.3.6. COVID- 19 Screening  
All subjects , including subjects aged 46 to 65 years, will be tested for COVID -19 (SARS -
CoV-2) at the time s indicated in the SoA ( Appendix 5),. Details of the testing will be 
provided separately. 
Throughout confinement, daily temperature will also be measured prior to any product use as 
part of the site’s COVID -19 measures/mitigation and will be captured separately from safety 
vital signs assessme nt. 
Subjects aged 46 to 65 must show proof that they were fully vaccinated for COVID-19 (SARS -CoV-2) at least 14 days before the screening visit. 
7.3.7. Tobacco Cessation Information 
The investigator (or designee) , at screening and at the EOS  or upon early termination, will 
advise all adult tobacco product users that to reduce the health effects of tobacco, the best thing to do is to quit. The investigator (or designee) will refer all adult tobacco product users to the Quit Assist
® website (using information cards, subject handouts, etc.), which contains 
citations  to a number of third-party information sources, including websites, telephone 
resources, and other organizations with additional information. 
8. DATA MANAGEMENT  
Data management activities will be detailed in the Data Management Plan (DMP). All data 
for this study will be captured in the Medrio system, supplied by ALCS  or designee. Medrio 
is 21 Code of Federal Regulations ( CFR ) Part 11 compliant. Electronic case report forms 
(eCRF) will be developed acco rding to the study protocol specifications and will follow 
ALCS data standards. Analytical data will be collected external ly to the database.  
Data will be captured on paper source and will be entered into the electronic data capture 
(EDC) system  by the site. All data captured will have an audit trail.  
Programmed edits checks will be used to ensure the accuracy and integrity of the database. Edit checks will be programmed within the system to check for errors and discrepancies, such 
as missing dat a, data inconsistencies , and inappropriate date ranges. Corrections will be made 
by the site as necessary prior to database lock. Database lock will occur after all reviews are completed, all queries are resolved , and there are no outstanding issues. Any changes to the 
data following database lock will be documented and approved by the sponsor prior to unlocking the database to make the required changes. 
Adverse events  will be coded using the most current version of the Medical Dictionary for 
Regulatory Act ivities ( MedDRA ). Concomitant medications will be coded using the most 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 32 of 51 current version of World Health Organization  Drug Dictionary. The versions will remain the 
same throughout the study. Coding will be completed by ALCS Data Management and will 
be review ed by the m edical monitor at ALCS  and Covance. 
All casebooks (e CRFs) will be signed by the investigator prior to database lock. Submission 
casebooks will be extracted after database lock and provided to the site.  
9. MONITORING OF THE STUDY  
The responsible study monitor will contact and visit the investigator as necessary, and he/she will be allowed, upon request, to inspect and verify all records of the study ( eg, source 
document, ICFs, eCRFs, regulatory documents) in a manner consistent with  good clinical 
practice ( GCP ) and all other applicable state and federal law.  
It will be the study monitor’s responsibility to inspect the source documents to verify the adherence to the protocol and the completeness, consistency, and accuracy of the data being entered in the eCRF. The monitor will verify that each subject has consented in writing prior to any study procedures being performed. Where the terms of the ICF, GCP, and all other 
applicable state and federal law permit, the monitor should have access to laboratory test 
reports and other subject records needed to verify the entries on the eCRF. The investigator (or designee) agrees to cooperate with the monitor to ensure that any issues detected in the course of these monitoring visit s are resolved. 
In addition, the sponsor’s internal auditors (or designee), institutional review board ( IRB) 
reviewers, and government inspectors may evaluate the study and must be allowed access to eCRFs, source documents, and other study files. 
The inves tigator must notify the sponsor (or designee) promptly of any inspections of the 
study or activities related to the study conducted by regulatory authorities, allow the sponsor 
(or designee) to be present during the inspection, and promptly forward copies of inspection reports to the sponsor (or designee). 
10. SAMPLE SIZE AND DATA ANALYSIS  
Full details of the statistical analysis methods for the study will be specified in the Statistical 
Analysis Plan. 
10.1. Determination of Sample Size 
Up to 150 subjects will be enrolled in order that 20 subjects per group complete the study.  
This study is being conducted to assess the differences in BOE  values after adult smokers 
switched to on!
® NP with the total NN AL (ng/24 h, measured at Day 7) as the primary 
endpoint. The sample size estimation is based on total NNAL data, assuming a two-sided test, 
85% power and α =0.017 Type I error rate to account for the multiplicity adjustment for the comparisons (each of the 3 NP groups ver sus CC group), a sample size of approximately 
20 subjects per group is needed to detect a statistically significant difference between the NP groups and CC group. Thirty subjects will be randomized to make sure 20 subjects per group complete the study. The sample size calculation used  to derive the sample size for this study 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 33 of 51 was based on summary statistics data of total NNAL from a previous study with a similar 
study design,9 where the mean ± standard deviation of total NNAL at Day 7 were 476.1 ± 
296.58 ng/24 h for the CC group and 167.3 ± 100.17 ng/24 h and 176.9 ± 135.17 ng/24 h for 
the groups that used a chewable OTDN product with 2 flavors, respectively. 
10.2. Analysis Populations 
10.2.1. Biomarker of Exposure Population 
The BOE population will include all subjects from Groups 1, 2, 3, and 4 who used at least 1 
of the assigned study products and all Group 5 subjects. To be included in the BOE 
population, subjects must have baseline (Day 1)  and at least 1 postbaseline evaluable BOE  
data.  
10.2.2. Safety Population 
The safety population will include all subjects from Groups 1, 2, 3, and 4 who used  at least 1 
of the assigned study product and Group 5 subjects. 
10.3. Biomarker of Exposure Analyses 
Urinary biomarkers:  
Linear mixed models for analysis of covariance will be used to compare the Day 7 biomarker 
values between groups as described in the study objectives. In the statistical models, the outcome variable will be included as a dependent variable; group and gender will be included as fixed effe cts; and baseline values of corresponding biomarker will be included as 
covariates. For the NP groups compared to the CC  group, Dunnett’s method will be used for 
the adjustment of multiple comparisons. The SAS procedure Proc Mixed will be used. The least-squares means (LSM) difference and 95% confidence interval for the LSM difference 
between the test and reference groups and p-values will be provided. 
10.4. Product Use Behavior  
The number of each product used per day (cigarettes o r NPs), NPPU , and the duration of each 
NP used during each product use period will be listed and summarized by study product using descriptive statistics, as appropriate.  
10.5. Safety Analysis 
All AEs will be listed and summarized using descriptive methodology. Each AE will be 
coded using MedDRA . Frequency counts of AEs will be provided by body system, preferred 
term, and study product. Frequency counts of AEs will also be summarized by severity and relationship to study product. 
Observed values for clinical laboratory test data, 12 -lead ECGs, vital signs, and physical 
examination findings will be listed.  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 34 of 51 10.6. Interim Analysis  
No interim analyses are planned for this study.  
  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 35 of 51 11. REFERENCES  
1. IARC. Tobacc o Control: Reversal of Risk after Quitting Smoking [Internet]. [cited 
2019 Mar 29]. Available from : http://publications.iarc.fr/Book -And-Report-
Series/Iarc-Handbooks- Of-Cancer -Prevention/Tobacco -Control- Reversal -Of-Risk-
After -Quitting -Smoking-2007 
2. World Health Organization  / WHO report on the global tobacco epidemic 2011 
[Internet]. [cited 2019 Mar 29]. Available from: 
http://www.who.int/tobacco/global_report/2011/en/ 
3. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General, 2014 [Internet]. [cited 2019 Mar 29]. Available from : 
https://www.ncbi.nlm.nih.gov/books/NBK179276 
4. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ . 1994; Oct 
8;309(6959):901-911. 
5. Zeller  M, Hatsukami  D. The Strategic Dialogue on Tobacco Harm Reduction: A 
Vision and Blueprint for Action in the US. Tob Control . 2009;18(4):324-332. 
6. Hatsukami DK, Joseph AM , Lesage M, et al. Developing the Science Base for 
Reducing Tobacco H arm. Nicotine Tob Res . 2007;9 Suppl 4(0 4):S537-553. 
7. Centers for Disease Control and Prevention. 2004 Surgeon General’s Reports: The Health Consequences of Smoking. Available from: https://www.cdc.gov/tobacco/data_statistics/sgr/2004/complete_report/index.htm  
8. Food and Drug Administration. Draft Guidance for Industry: Modified Risk Tobacco Product Applications [Internet]. 2012. Available from: .https://www.fda.gov/media/135135/download. 
9. Altria; Study Report No: ALCS -RDS -18-04- VRV.  
10. ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (E2A). Federal Register . 1995;60:11284. 
11. E6(R2 ) Good Clinical Practice: Integrated Addendum to E6(R1); International 
Council for Harmonisation; Guidance for Industry. Federal Register . 
2018;83:8882-8883. 
12. Nebeker JR, Barach P, Samore MH. Clarifying Adverse Drug Events: A Clinician’s Guide to Terminology, Documentation, and Reporting. Ann Intern Med. 2004; 140:795-801. 
13. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet . 2000; 356:1255-1259. 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 36 of 51 14. Fagerstr öm K, Russ C, Yu CR, Yunis C, Foulds J. The Fagerström Test for  
Nicotine Dependence as a Predictor of Smoking Abstinence: A Pooled Analysis of 
Varenicline Clinical Trial Data. Nicotine Tob Res . 2012;14:1467-1473.   
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Protocol Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021 Page 37 of 51 12. APPENDICES  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Proto col Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021  Page 38 of 51 Appendix  1: Adverse Event Reporting  
Definitions  
The following is the definition for an AE :  
Any unfavorable and unintended sign (including an abnormal laboratory finding10), symptom, 
or disease10 temporally associated with the use of a study product, whether or not related to 
the study product.10, 11 
All AEs occurring during this study after the sub ject has signed the ICF and after the first  use 
of the study product during the Product Trial and through Day 8 or EOS /Early Termination 
must be recorded in the eCRF, including the date and time of onset and outcome of each 
event. Events occurring between signing of the ICF and prior to the first use of study product during the Product Trial will be documented as medical history.  
Surgical procedures themselves are not AEs; they are therapeutic measures for conditions that 
require surgery. The condition for which the surgery is required may be an AE. Planned  
surgery permitted by the clinical study protocol and the condition(s) leading to this surgery are not AEs.  
No causal relationship with the study products or with the clinical study itself is implied by 
the use of the term “adverse event.”  
Assessment of Severity  
The investigator (or designee) will review each event and rate each reported sign or symptom 
on a 3-point severity scale. The following definitions for rating severity
10 will be used:  
• Mild: The AE is easily tolerated and does not interfere with daily activity  
• Moderate: The AE interferes with daily activity, but the subject is still able to function  
• Severe: The AE is incapacitating and requires medical intervention. Note: This is not 
the same as “serious,” which is based on the outcome or action criteria usually associated with events that pose a threat to life or functioning. 
Relationship to Study Product  
Each AE will also be assessed by the investigator (or designee) for relationship to study 
product (causality) using the following grades of certainty
12, 13 (the strength of a causal 
association may be revised as more information becomes available):  
Not related: Clearly an d definitely due to extraneous cause ( eg, disease, environment)  
Unlikely:  
a. Does not follow a probable temporal ( ie, time) sequence from the use of 
study product.  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Proto col Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021  Page 39 of 51 b. Does not follow a known pattern of response to the study product.  
c. Could plausibly have been produced by the subject’s clinical 
state/underlying disease or other drugs or chemicals the subject received.  
d. Does not reappear or worsen when the study product is re- administered.  
Possible:  
a. Follows a reasonable temporal ( ie, time) sequence from the use of study 
product.  b. Follows a known pattern of response to the study product.  c. Could also have been produced by the subject’s clinical state/concurrent 
disease or other drugs or chemicals the subject received.  
Likely:  
a. Follows a reasonable temporal ( ie, time) sequence from the use of study 
product.  
b. Follows a known pattern of response to the study product.  c. Could not readily have been produced by the subject’s clinical 
state/concurrent disease or other drugs or chemicals.  
d. Follows a clinically reasonable response on withdrawal (dechallenge), ie , 
disappears or decreases  when the study product is stopped or reduced.  
e. Rechallenge information is not required to fulfill this definition.  
Definitely:  
a. Follows a reasonable temporal ( ie, time) sequence from the use of study 
product.  b. Follows a known pattern of response to the study product.  c. Cannot be explained by the subject’s clinical state/concurrent disease or 
other drugs or chemicals.  
d. Follows a clinically reasonable response on withdrawal (dechallenge), ie , 
disappears or decreases when the study product is stopped or reduced.  e. Recurs with re-exposure to study product (rechallenge). NOTE: 
Re-exposure of the subject is NOT required, but the “definitely related” 
category may only be used when recurrence is observed.  
 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Proto col Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021  Page 40 of 51 Follow- up of Adverse Events  
Every reasonable effort will be made to follow up with subjects who have ongoing AEs  at the 
EOS visit. Any subject who has an ongoing AE that is possibly related or related to the study 
product or study procedures at the EOS  visit will be followed up, where possible, until 
resolution or until the unresolved AE is judged by the investigator (or designee) to have stabilized. This will be completed at the investigator’s (or designee’s) discretion. Any subject 
who has an ongoing AE that is not related or unlikely related to the study product or study 
procedures at the EOS  visit can be closed out as ongoing at the investigator’s discretion.  
Serious Adverse Events  
An SAE  is defined as any untoward medical occurrence that either:  
• Results in death  
• Is life -threatening 
• Requires inpatient hospitalization or prolongation of existing hospitalization 
• Results in persistent or significant disability/incapacity (disability is define d as a 
substantial disruption of a person’s ability to conduct normal life functions) 
• Results in a congenital anomaly/birth defect 
• Results in an important medical event (see below).  
Important medical events that may not result in death, be life -threatening , or require 
hospitalization may be considered SAEs when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. 
Instances of death  or congenital abnormality, if brought to the attention of the investigator at 
any time after cessation of the study product and considered by the investigator  to be possibly 
related to the study product, will be reported to the sponsor. 
Definition of Life -threatening 
An AE is life -threatening if the subject was at immediate risk of death from the event as it 
occurred (ie, does not include a reaction that might have caused death if it had occurred in a 
more serious form). For instance, drug-induced hepatitis that resolved without evidence of hepatic failure would not be considered life-threatening even though drug-induced hepatitis can be fatal.  
Definition of Hospitalization  
Adverse events requiring hospitalization should be considered serious. In general, hospitalization signifies that the subject has been detained (usually involving an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate at the study site. When in doubt as to whether hospitalization occurred or was necessary, the AE should be considered as serious. 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Proto col Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021  Page 41 of 51 Hospitalization for elective surgery or routine clinical procedures, which are not the result of 
an AE, need not be considered AEs and should be recorded on a clinical assessment form and added to the e CRF . If anything untoward is reported during the procedure, this must be 
reported as an AE and either ‘serious’ or ‘nonserious’ attributed according to the usual criteria.  
Serious Adverse Event Reporting  
AEs that are associated with the use of the study product and are serious and unexpected will 
be reported by the study site to the sponsor, m edical monitor assigned by the sponsor, and the 
responsible IRB.  
The sponsor and medical monitor will be notified in writing (eg, facsimile , email/attachment) 
within 24 hours of when a serious, unexpected AE that is associated with use of the study 
product associated is first recognized or reported. 
Subsequently, a written confirmation or summary of the AE (using ALCS SAE Report Form ) 
will be sent to the sponsor within 3 working days of the original notification.  
The IRB will be notified of any serious, unexpected AE that is associated with the use of the 
study product in accordance with the IRB’s procedures.  
Pregnancy 
A positive pregnancy test prior to enrollment will be documented as a screen failure. 
Pregnancy occurring in a female study subject (after check -in through EOS /Early 
Termination) will be documented in a pregnancy form (provided separately) and as a protocol deviation to the IRB.  
Pregnancy itself is not an AE. The investigator or designee will discontinue the pregnant 
subject from the study and will advise her to seek prenatal care and counseling from her primary care provider. The investigator (or designee) will refer her to the Quit Assist
® 
website, which contains citations to a number of third-party information sources, including websites, telephone resources , and other organizations with additional information. Advice 
given will be documented in the subject’s source document. 
All pregnancies must be reported by telephone and by fax or email to the sponsor and the 
medical monitor within 24 hours of the site’s learning of the pregnancy or, at the latest, on the following workday. The ALCS Pregnancy Report Form should be completed to report a summary within 3 working days. 
The study site staff will request the pregnant subject to notify the site of the outcome of the 
pregnancy ( ie, birth, loss, or termination). To help ensure this, the study site staff will follow 
up with the subject until the end of pregnancy, if in compliance with the site’s standard operating procedures and with the subject’s consent. This request and the subject’s response will be documented in the subject’s source document. A final report of pregnancy outcome will be sent to the medical monitor.   
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Proto col Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021  Page 42 of 51 Appendix  2: Clinical Laboratory Evaluations 
Clinical chemistry:  Hematology: Urinalysis:  
Alanine aminotransferase  
Albumin  
Alkaline phosphatase  
Aspartate aminotransferase  
Bicarbonate  
Blood urea nitrogen  
Chloride  
Creatininec 
Glucose  
Potassium   
Sodium  
Total bilirubina 
Total protein  
Uric acid  Hematocrit   
Hemoglobin  
Platelet count Red blood cell (RBC) count  
White blood cell (WBC) count  
WBC differential:    Basophils  
   Eosinophils  
   Lymphocytes  
   Monocytes  
   Neutrophils  
 Bilirubin  
Blood 
Color and appearance  
Glucose  
Ketones  
Leukocyte esterase  
Nitrite  
pH 
Protein  
Specific gravity  
Urobilinogen  
Microscopic examinationd (RBCs, 
WBCs, casts, and bacteria)  
Serology: Drug screen:  Hormone panel - females 
only: 
Hepatitis B surface antigen  
Hepatitis C antibody  
Human immunodeficiency virus  
(HIV -1 and HIV -2) antibodies  Including but not limited to:  
Amphetamines/methamphetamines  
Cocaine (metabolite)  
Opiates  
Tetrahydrocannabinol/cannabinoids  
Alcohol  
Cotinine teste Follicle -stimulating hormonef 
(postmenopausal females only)  
Serum pregnancy testg (human 
chorionic gonadotropin)  
Urine pregnancy testb  
a Direct and indirect bilirubin will be analyzed  if total bilirubin is elevated .  
b Performed for  all females  at check -in. A positive urine pregnancy test will be confirmed with a serum pregnancy test.  
c At screening , estimated glomerular filtration rate  will be calculated . 
d Microscopic examination will be conducted if protein,  leukocyte esterase, nitrite , and/or blood are abnormal.  
e A positive qualitative test (≥ 500 ng/mL) will be required for participation in the study . 
f To confirm postmenopausal status . 
g Performed for all females at screening .  
 
 
In addition, COVID-19 (SARS -CoV-2) testing will be performed at screening and check -in. 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Proto col Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021  Page 43 of 51 Appendix  3: Contraception Guidance  
Definitions  
Women of Childbearing Potential: premenopausal females who are anatomically and 
physiologically capable of becoming pregnant following menarche. 
Women of Non childbearing  Potential:  
1. Surgically sterile:  females who are permanently sterile via hysterectomy, 
bilateral salpingectomy , and/or bilateral oophorectomy by reported medical 
history and/or medical records. Surgical sterilization to have occurred a minimum 
of 6 months, or at the investigator’s discretion, prior to s creening . 
2. Postmenopausal: f emales at least 45 years of age wit h amenorrhea for 12 months 
without an alternative medical reason with confirmatory FSH levels of 
≥40 mIU/mL. The amenorrhea should not be induced by a medical condition such as anorexia nervosa, hypothyroid disease, or polycystic ovarian disease or by extreme exercise. It should not be due to concomitant medications that may have 
induced the amenorrhea such as oral contraceptives, hormones, gonadotropin-releasing hormones, anti-estrogens, or selective estrogen receptor modulators.  
Contraception Guidance  
Female Subjects  
Female subjects who are heterosexually active and of childbearing potential (eg , not 
surgically sterile at least 6 months prior to check -in nor postmenopausal with amenorrhea for 
at least 12 months prior to check-in and FSH levels consistent with postmenopausal status) 
must have been using one of the following forms of contraception and agree to continue using it through completion of the study: 
• Hormonal ( eg, oral, vaginal ring, transdermal patch, implant, injection) consistently 
for at least 3 months prior to c heck -in 
• Double barrier ( eg, condom with spermicide or diaphragm with spermicide) 
consistently for at least 4 weeks prior to c heck -in 
• Intrauterine devi ce for at least 4 months prior to c heck -in 
• Exclusive partner who has been vasectomized for at least 6 months (inclusive) prior to 
check -in. 
Female subjects of childbearing potential who are not currently engaging in heterosexual 
intercourse must agree to u se one of the above methods of birth control through completion 
of study, in the event that they have heterosexual intercourse during the course of the study. 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Proto col Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021  Page 44 of 51 Appendix  4: Regulatory, Ethical, and S tudy Oversight Considerations 
Regulatory and Ethic al Co nsiderations  
This study will be conducted in accordance with the protocol and with the following: 
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines . 
• Applicable International Conference on Harmonization (ICH) GCP Guidelines. 
• Applicable laws and regulations. 
The protocol, protocol amendments, ICF, and other relevant documents must be submitted to an IRB by the investigator and reviewed and approved by the IRB before the study is 
initiated.  
Any amendments to the protocol will require IRB approval before implementation of changes made to the study design, except for changes necessary to eliminate an immedi ate hazard to 
study subjects .  
The investigator will be responsible for the following: 
• Providing written summaries of the status of the study to the IRB  annually or more 
frequently in accordance with the requirements, policies, and procedures established by the IRB . 
• Notifying the IRB  of SAEs  or other significant safety findings in accordance with the 
IRB’s procedures . 
• Providing oversight of the conduct of the study at the site and adherence to requirements of ICH guidelines and all other applicable regulations. 
Finances and Insurance  
Financing and insurance will be addressed in a separate agreement. 
Informed Consent  
Prior to starting participation in the study, each subject will be provided with a study- specific 
ICF giving details of the study products, procedures, and potential risks of the study. Subjects 
will be instructed that they are free to obtain further information from the investigator  (or 
designee) and that their participation is voluntary and they are free to withdraw from the study at any time.
 Subjects will be given an opportunity to ask questions about the study prior 
to providing consent for participation. 
Following discussion of the study with study site personnel, subjects will sign the ICF in the 
presence of a suitably trained member of staff to indicate that they are freely giving their informed consent. A copy of the ICF will be given to the subjects. 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Proto col Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021  Page 45 of 51 If the ICF is amended at any time after subjects have started participating in the study, those 
subjects must be re-consented to the most current version of the ICF(s) during their participation in the study. 
Subject Data Prote ction 
Subjects will be assigned a unique identifier and will not be identified by name in eCRFs, 
study-related forms, study reports, or any related publications. Subject and investigator personal data will be treated in compliance with all applicable laws and regulations. In the event the study protocol, study report, or study data are included in a public registry, all identifiable information from individual subjects or investigators will be redacted according to applicable laws and regulations.  
The subject mu st be informed that his/her personal study- related data will be used by the 
sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the subject. The subject must also be informed that his/her study- related data 
may be examined by sponsor or contract research o rganization ( CRO)  auditors or other 
authorized personnel appointed by the sponsor, by appropriate IRB members, and by 
inspectors from regulatory authorities. 
Disclosure All information provided regarding the study, as well as all information collected and/or 
documented during the course of the study, will be regarded as confidential. The investigator (or designee) agrees not to disclose such information in any way without prior written permission from the sponsor. 
Data Quality Assurance The following data quality steps will be implemented: 
• All relevant subject data relating to the study will be recorded on eCRFs unless 
directly transmitted to the sponsor or designee electronically (eg , laboratory data). The 
investigator is responsible for verifying that data entries are accurate and correct by 
electronically signing the eCRF.  
• The investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.  
• The investigator must permit study -related monitoring, audits , IRB review, and 
regulatory agency inspections and provide direct access to source data documents.  
• The sponsor or designee is responsible for the data management of this study 
including quality checking of the data. Predefined agreed risks, monitoring thresholds, quality tolerance thresholds, controls, and mitigation plans will be documented in a risk management register. Additional details of quality checking to be performed on the data may be included in a DMP .  
• A study monitor will perform ongoing source data verification to confirm that data 
entered into the eCRF by authorized site personnel are accurate, complete, and 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Proto col Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021  Page 46 of 51 verifiable from source documents; that the safety and rights of subjects are being 
protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements. 
• Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the investigator for a minimum of 20 years after the completion or termination of the study. No records may be destroyed during the retention period without the written approval of the sponsor. No records may be transferred to another location or party without written notification to the sponsor.  
Investigator Documentation Responsibilities 
All individual, subject-specific study data will also be entered into a 21 CFR 
Part 11-compliant EDC system on an eCRF in a timely fashion . 
All data generated from external sources (eg, laboratory and bioanalytical data), and transmitted to the sponsor or designee electronically, will be integrated with the subject’s 
eCRF data in accordance with the DMP .  
An eCRF  must be completed for each enrolled subject who undergoes any screening 
procedures, according to the eCRF completion instructions. The sponsor , or CRO, will 
review the supporting source documentation against the data entered into the eCRFs to verify the accuracy of the electronic data. The investigator will ensure that corrections are made to 
the eCRFs and that data queries are resolved in a timely fashion by the study staff. 
The investigator will sign and date the eCRF via the EDC system’s electronic sign ature 
procedure. These signatures will indicate that the investigator reviewed and approved the data 
on the eCRF, data queries, and site notifications. 
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Proto col Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021  Page 47 of 51 Appendix  5: Schedule of Assessments  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Proto col Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021  Page 48 of 51 Study Procedures  Screening  Days  -3 to -1f Days 1  (Baseline)  to 7 EOS  (Day 8 ) or Early Termination  
Informed consent  X    
Inclusion/exclusion criteria  X X (Day -3)   
Demographic data  X    
Medical history  X X (Day -3)a   
Tobacco use historyb X    
Fagerström Test for 
Cigarette Dependencet 
(Appendix 6 )   X (Day 1, only)  
Urinary drug screen  X X (Day -3)   
Cotinine test  X    
Alcohol breath test  X  X (Day -3)   
Serologyc X    
Pregnancy testd X X (Day -3)   
FSHe X    
Height , body weight , and 
BMI  X    
COVID -19 test  X X (Day -3)   
Tobacco Cessation 
Information  X   X 
Study residency:      
Check -in  X (Day -3)   
Check -out    X (after last Day 7 urine collection)  
Study product 
administrationg:     
Product trial   Xh (Day -3, only)    
Randomizationi   Day 1   
2 mg  NP (Group 2)    Xj (ad libitumk)  
4 mg NP (Group 3)    Xj (ad libitumk)  
8 mg  NP (Group 4)    Xj (ad libitumk)  
UBC  (Group 1)    Xl (ad libitumm)  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Proto col Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021  Page 49 of 51 Study Procedures  Screening  Days  -3 to -1f Days 1  (Baseline)  to 7 EOS  (Day 8 ) or Early Termination  
No Tobacco (Group 5)    X  
Pharmacokinetics:      
Blood samplingn  X (Day -1, only)  X (Day 7, only)   
24-hour urine samplingo  X (Day -1, only)  X (Day 7, only)   
Urine creatininep  X (Day -1, only)  X (Day 7, only)   
Safety:      
Adverse event recording   X Ongoing  X 
Prior/concomitant 
medication monitoring  X X Ongoing X 
Clinical laboratory 
evaluationsq X    
Vital signsr X X  X X 
12-lead ECG  X    
Physical examinations X X (Day -3)  X 
Abbreviations: BMI = body mass index; BOE  = biomarker of exposure; COHb = carboxyhemoglobin; COVID = coronavirus disease  (SARS-CoV-2) ; CPD = cigarettes smoked per day; ECG = 
electrocardiogram ; EOS  = end of the study; FSH = follicle -stimulating hormone ; HBsAg = hepatitis B surface antigen; HCV = hepatitis C virus; HIV= human immunodeficiency virus; NP = 
nicotine pouch; UBC  = usual brand cigarettes .  
a Interim medical history . 
b The following characteristics of the subject’s usual brand will be documented: brand, brand style, and flavor. The number of uses per day (single number, not a range) will also be documented. 
Subjects will bring with them a new pack of their most commo nly used cigarettes. The pack will be color photocopied and the copy will be placed in the source documents at screening and at 
any time during the study in which the subject changes cigarette brand.  
c HIV, HBsAg, HCV tests. 
d Serum  pregnancy  test f or all females  at screening; urine pregnancy test for all females at check -in. A positive urine pregnancy test will be confirmed with a serum pregnancy test.  
e To confirm postmenopausal status in self-reported postmenopausal females only.  
f Following Product Trial  on Day -3, subjects will continue to smoke their UBC s through 23:00 on Day -3 and from 07:00 to 23:00 on Days -2 and -1.  
g Product use will not be permitted from 23:00 to 07:00 each day during the study from check -in (Day -3) until Day 7. Product use and cigarette smoking will not be allowed at Day 8 ( EOS ). 
h Subjects will engage in a brief Product Trial  using one 8 mg  NP for 10 minutes to allow subjects to become accustomed to the products.  
i Subjects will be randomized into each group on Day 1 based on gender and CPD . In order to make study product preparation for Day 1 easier and more manageable for the site, randomization 
of study subjects will also be allowed after 19:00 on Day - 1. 
j Subjects will be allowed to use the NPs upon request and they will be instructed to return each used NP upon completion.  
k No restrictions on the number of NP used at once, the number of NP used per day, or the duration of use  except for 3 specific NP use opportunities at approximately 11:00, 15:00, and 19:00 
each day during which subjects will be asked to keep the assigned NP in their mouth for at least 10 minutes.  
l Subjects will be allowed to smoke upon request to the clinic staff but will only be allowed 1 cigarette at a time and will be instructed to return each cigarette butt upon completion. 
m No restriction on the duration of use or the number of CPD.  
Protocol Amendment 2 CONFIDENTIAL  
Covance Study: 000000215511 Proto col Reference: ALCS -REG -20-15- OTDN  
Final Protocol Amendment 2, 30 June 2021  Page 50 of 51 n At approximately 21:30. The sample will be used for COHb analysis.  
o All urine voids over a 24- hour period (24- hour urine) will be collected for BOE analysis. The 24-hour urine collection begins on each scheduled day after the first morning void and any void 
prior to 07:00, and finishes the following morning with the last void collected at approximately 07:00 (including first morni ng void).  
p Urine creatinine will b e measured in each 24 -hour collection and may be used to adjust the concentration values of urine BOEs.  
q Hematology, clinical chemistry, routine urinalysis  (see Appendix 2) at screening .  
r Blood pressure, heart  rate, respiratory rate, and oral temperature. All vital signs assessed at screening, Day -3 and EOS.  From Day -2 to Day 7: d aily oral temperature only .  
s A general  physical examination at screening ; symptom -directed physical examination s at other timepoints . 
t The Fagerström Test for Cigarette Dependence should be completed in the morning of Day 1 before any study product use.  
 
Pr ot oc ol A me n d me nt 2 C O N FI D E N TI A L  
C o va nce St u d y: 0 0 0 0 0 0 2 1 5 5 1 1 Pr ot o c ol Refere n ce: A L C S -R E G - 2 0- 1 5- O T D N  
Fi nal Pr ot oc ol A me n d me nt 2, 3 0 J u ne 2 0 2 1  Pa ge 5 1 of 5 1 A p pe n di x  6 : F a gerstr ö m Test f or Ci g arette D e pe n de nce 1 4  Q uesti o n n aire  
 
 
1.  H o w s o o n after y o u wa k e u p d o y o u s m o ke y o ur first ci garette? 
  Wit hi n 5 mi n utes ( 3) 
  6- 3 0 mi n utes ( 2) 
  3 1- 6 0 mi n utes ( 1) 
 Afte r 6 0 mi n utes ( 0) 
 
2.  D o y o u fi n d it diffic ult t o refr ai n fr o m s m o ki n g i n places w here it is 
f or bi d de n? 
 Yes ( 1)  
  N o ( 0) 
 
3.  W hic h ci gar ette w o ul d y o u hate m ost t o gi ve u p? 
  T he first o ne i n t he m or ni n g ( 1) 
  All ot hers ( 0) 
 
4.  H o w ma n y ci garettes/ da y d o y o u s m o ke? 
  1 0 or less ( 0) 
  1 1- 2 0 ( 1) 
  2 1- 3 0 ( 2) 
  3 1 or m ore ( 3) 
 
5.  D o y o u s m o ke m ore fr e q ue ntl y d uri n g t he first h o urs after wa ki n g t ha n d uri n g 
t he rest of t he da y ?  
 Yes ( 1)  
  N o ( 0) 
 
6.  D o y o u s m o ke if y o u ar e s o ill t hat y o u are i n be d m ost of t he da y? 
 Yes ( 1)  
  N o ( 0) 